• The new name reflects a bold vision to eradicate cancer by leveraging the transformative power of global collaboration and multi-sectoral partnerships
• Nasdaq stock symbol changed to ONC

-Beigene, a global oncology company, has announced its intention to change its name to BeOne Medicines Ltd. The name change underpins our determination to develop innovative medicines that fight cancer by partnering with communities around the world and serving as many patients as possible.

"We have already helped more than 1.4 million patients, have one of the most complete oncology pipelines, and are currently on track to introduce more than 10 new and potential therapies into clinical trials, and we look forward to moving into the next phase of growth as BeOne."

John V. Euler, co-founder, chairman and CEO of Beigene, said, "Cancer, the leading cause of death worldwide, is costing individuals, families and communities profoundly. Individuals, families, scientists, clinicians, hospitals, lawmakers, corporations, and even nations cannot and will not stand alone against this devastating disease. We must all work together to win. That's why we play an important role in the fight against cancer and are committed to uniting communities around the world. We are not only focused on bringing innovative medicines to as many people as possible, but also on identifying and solving challenges that impede access to treatment. By doing so, we can make treatment more accessible and affordable," he said, adding, "We already support more than 1.4 million patients, have one of the most complete oncology pipelines, and are currently on track to introduce more than 10 new and potential therapies into clinical trials.

BeOne Medicines, an evolved brand

The proposed new name and logo reflect our commitment to uniting in the fight against cancer. A new logo design was created based on this.

• The "Be" represents the underlying goal of cancer patients: to overcome the disease.
• "One" emphasizes our unity as a team and represents our shared mission of patients, caregivers, scientists, healthcare professionals, governments, and industry to work together to eradicate cancer.
• The word "Onc" in "One" is written in red, emphasizing the commitment to cancer treatment.
• In addition, the power button in the final "e" represents the company's approach of always being "on" in pursuit of new medicines that disrupt the main drivers of cancer cell growth and survival, harness the body's immune system to attack tumors, and "turn off" cancer by targeting specific biomarkers of cancer. The angled angle of the button represents our path to pushing the boundaries of science.

The new name is part of a broader strategic growth plan that has underpinned global oncology leadership since its inception in 2010. Recently, we reported significant growth in product sales in the United States and Europe, resulting in total quarterly revenue reaching $1 billion. To support the expansion of its clinical portfolio and global growth, the company opened an $800 million clinical R&D and manufacturing flagship facility at the Princeton West Innovation Campus in Hopewell, New Jersey, in July. Upon approval by shareholders, the stock symbol on the Nasdaq will be changed to "ONC".

The company's nearly 11,000 employees have advanced more than 20 molecules into clinical trials and received regulatory approvals on five continents. Our unique global clinical team of more than 1,800 employees conducts clinical trials in more than 45 countries across Europe, North and South America, Australia and Asia. Our portfolio strategy focuses on the rapid generation of proof-of-concept data in the early clinical stages, leveraging the speed and cost advantages of global clinical operations ("Fast to Proof of Concept"). In addition, BRUKINSA (zanubrutinib), which has the widest range of indications among BTK inhibitors, has become a leader in the field of hematology. In the U.S., we are the top candidate for all approved B-cell malignancies, as well as for the number of new patients initiated for both first-time treatment and recurrence and refractory chronic lymphocytic leukemia. Approved in more than 70 markets, this high-impact treatment is being promoted as the linchpin of our blood disease franchise as monotherapy and as the backbone of a potentially best-in-class combination therapy with the late-stage BCL2 inhibitor sonorotoclax and the BTK-degrading agent BGB-16673. IN ADDITION, WE ARE FOCUSING ON EXPANDING OUR LEADERSHIP IN SOLID ONCOLOGY WITH THE PD-1 INHIBITOR TEVIMBRA (TICILELIZUMAB). We are also developing assets that have the potential to be best-in-class for breast, lung, and gastrointestinal cancers across multiple modalities, including antibody-drug conjugates, multispecific antibodies, targeted proteolytics, and small molecule inhibitors. ^® ®